Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 13/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113638 | 0.86 | PTPN1 (0.55) | RAB9AALDH1A1SMN1; SMN2MCHR1KCNH2 | |
| SCHEMBL167013 | 0.84 | MCHR1 (0.51) | RAB9AALDH1A1SMN1; SMN2SMPD1MCHR1 | |
| SCHEMBL175935 | 0.84 | MCHR1 (0.65) | MCHR1KCNH2HRH3 | |
| SCHEMBL27851472 | 0.76 | MAPK1 (0.69) | RAB9AALDH1A1SMN1; SMN2SMPD1LMNA | |
| SCHEMBL326809 | 0.75 | MCHR1 (0.85) | MCHR1KCNH2HRH3 | |
| SCHEMBL326606 | 0.75 | PTPN1 (0.72) | RAB9AALDH1A1SMN1; SMN2SMPD1LMNA | |
| SCHEMBL3823166 | 0.73 | SMPD1 (0.65) | RAB9AALDH1A1SMN1; SMN2SMPD1LMNA | |
| SCHEMBL17377393 | 0.73 | PTPN1 (0.70) | RAB9AALDH1A1SMN1; SMN2SMPD1LMNA | |
| SCHEMBL326919 | 0.72 | MCHR1 (0.74) | MCHR1KCNH2HRH3 | |
| Lithium Ion SCHEMBL17377391 | 0.72 | SMPD1 (0.63) | RAB9AALDH1A1SMN1; SMN2SMPD1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424870-B1 | Therapeutic agents 713 | ASTRAZENECA AB (SE) | 2015-12-16 | — | — | EP | disclosed |
| EP-2424870-B1 | Therapeutic agents 713 | ASTRAZENECA AB (SE) | 2015-12-16 | — | — | EP | disclosed |
| EP-2424870-A1 | THERAPEUTIC AGENTS 713 | AstraZeneca AB (SE) | 2012-03-07 | — | — | EP | disclosed |
| US-8110566-B2 | Therapeutic agents 713 | ASTRAZENECA AB (SE) | 2012-02-07 | — | — | US | disclosed |
| US-8110566-B2 | Therapeutic agents 713 | ASTRAZENECA AB (SE) | 2012-02-07 | — | — | US | disclosed |
| US-8110566-B2 | Therapeutic agents 713 | ASTRAZENECA AB (SE) | 2012-02-07 | — | — | US | disclosed |
| WO-2010125390-A1 | THERAPEUTIC AGENTS 713 | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010125390-A1 | THERAPEUTIC AGENTS 713 | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | WO | disclosed |
| US-20100280000-A1 | THERAPEUTIC AGENTS 713 | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280000-A1 | THERAPEUTIC AGENTS 713 | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
| US-20100280000-A1 | THERAPEUTIC AGENTS 713 | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280000-A1 | THERAPEUTIC AGENTS 713 | MC1R, MC2R, MC3R | RAB9A 871/4885ALDH1A1 675/4885SMN1; SMN2 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.